You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


Advertisement

ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | RSS | Access Rights | Sign In


  Vol. 153 No. 10, 24 MAY 1993 TABLE OF CONTENTS
  Online Only
 •  Online First Table of
Contents
  Original Investigations
 •Online Features
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (73)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Delicious Add to Digg Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this?

Human Immunodeficiency Virus Counseling, Testing, Referral, and Partner Notification Services

A Cost-Benefit Analysis

David R. Holtgrave, PhD; Ronald O. Valdiserri, MD, MPH; A. Russell Gerber, MD; Alan R. Hinman, MD, MPH

Arch Intern Med. 1993;153(10):1225-1230.


Abstract



Background
The Centers for Disease Control and Prevention (Atlanta, Ga) annually provides more than $100 million in funding to states, territories, and cities for the provision of human immunodeficiency virus (HIV) counseling, testing, referral, and partner notification (CTRPN) services. Given the size of this expenditure, it is important to consider the net benefits of this program activity. We compared the economic costs and benefits of publicly funded HIV CTRPN services.

Methods
Standard methods for cost-benefit analysis were used. A societal perspective was employed. Major assumptions used in the base-case analysis included the following: (1) without public funding, the HIV CTRPN services would not be provided; (2) for every 100 HIV-seropositive persons identified and reached by CTRPN services, at least 20 new HIV infections are averted; and (3) for every $100 spent on direct and indirect costs of CTRPN services, approximately another $60 is spent on the ancillary costs of alerting people to HIV issues and CTRPN service availability. Sensitivity analyses were performed to explore the robustness of base-case results to these and other changes in model assumptions.

Results
Under base-case assumptions, the combined direct, indirect, and ancillary costs of the CTRPN program in 1990 dollars were $188 217 600. At a 6% discount rate, the estimated economic benefits of this expenditure are $3 781 918 000. The resultant benefit-cost ratio is 20.09. Sensitivity analyses showed that the benefit-cost ratio is greater than 1 for all considered cases.

Conclusions
This cost-benefit analysis strongly suggests that publicly funded CTRPN services result in a net economic gain to society.

(Arch Intern Med. 1993;153:1225-1230)



Author Affiliations



From the National Center for Prevention Services, Centers for Disease Control and Prevention, Atlanta, Ga.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Delicious Delicious   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

One to one interventions to reduce sexually transmitted infections and under the age of 18 conceptions: a systematic review of the economic evaluations
Barham et al.
Sex. Transm. Infect. 2007;83:441-446.
ABSTRACT | FULL TEXT  

Trends in Human Immunodeficiency Virus Seroincidence among Street-Recruited Injection Drug Users in San Francisco, 1987-1998
Kral et al.
Am J Epidemiol 2003;157:915-922.
ABSTRACT | FULL TEXT  

Economic Evaluation of Safer Choices: A School-Based Human Immunodeficiency Virus, Other Sexually Transmitted Diseases, and Pregnancy Prevention Program
Wang et al.
Arch Pediatr Adolesc Med 2000;154:1017-1024.
ABSTRACT | FULL TEXT  

Cost-Effectiveness of Universal Compared With Voluntary Screening for Human Immunodeficiency Virus Among Pregnant Women in Chicago
Immergluck et al.
Pediatrics 2000;105:e54-e54.
ABSTRACT | FULL TEXT  

Economic Impact of Treatment of HIV-Positive Pregnant Women and Their Newborns With Zidovudine: Implications for HIV Screening
Mauskopf et al.
JAMA 1996;276:132-138.
ABSTRACT  

Threshold Analysis and Programs for Prevention of HIV Infection
Holtgrave and Qualls
Med Decis Making 1995;15:311-317.
ABSTRACT  

The Cost-effectiveness of Voluntary Counseling and Testing of Hospital Inpatients for HIV Infection
Lurie et al.
JAMA 1994;272:1832-1838.
ABSTRACT  

HIV prevention programs
Holtgrave and Qualls
Science 1994;266:16-16.
 

Evaluating Behavioral Interventions: Need for Randomized Controlled Trials-Reply
Peterman and Aral
JAMA 1994;271:1318-1318.
ABSTRACT  

Evaluating Behavioral Interventions: Need for Randomized Controlled Trials
Gerber et al.
JAMA 1994;271:1317-1318.
ABSTRACT  

The Cost-effectiveness of HIV Testing of Physicians and Dentists in the United States
Phillips et al.
JAMA 1994;271:851-858.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | PHYSICIAN JOBS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1993 American Medical Association. All Rights Reserved.